Page last updated: 2024-09-05

orantinib and Neoplasms, Pleural

orantinib has been researched along with Neoplasms, Pleural in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akiyama, S; Dat, le T; Goto, H; Hanibuchi, M; Kakiuchi, S; Kuramoto, T; Nishioka, Y; Sakaguchi, S; Sato, S; Sone, S; Van, TT; Yukishige, S	1

Other Studies

1 other study(ies) available for orantinib and Neoplasms, Pleural

Article	Year
SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model. Respirology (Carlton, Vic.), 2012, Volume: 17, Issue:6 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Fibroblast Growth Factor 2; Humans; Indoles; Male; Mesothelioma; Mice; Mice, SCID; Neovascularization, Pathologic; Oxindoles; Pleural Effusion, Malignant; Pleural Neoplasms; Propionates; Protein Kinase Inhibitors; Pyrroles; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2012

Article

Year

SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.

Respirology (Carlton, Vic.), 2012, Volume: 17, Issue:6

Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Fibroblast Growth Factor 2; Humans; Indoles; Male; Mesothelioma; Mice; Mice, SCID; Neovascularization, Pathologic; Oxindoles; Pleural Effusion, Malignant; Pleural Neoplasms; Propionates; Protein Kinase Inhibitors; Pyrroles; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2012